Eiji Kakazu1, Yasuteru Kondo2, Masashi Ninomiya2, Osamu Kimura2, Futoshi Nagasaki3, Yoshiyuki Ueno4, Tooru Shimosegawa2. 1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan. kakazu@coral.ocn.ne.jp. 2. Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aobaku, Sendai, 980-8574, Japan. 3. Department of Gastroenterology, Sendai City Hospital, 3-1, Shimizukoji, Wakabayashiku, Sendai, Miyagi, 984-8501, Japan. 4. Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Abstract
BACKGROUND AND AIMS: The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatitis (NASH). Thus, we investigated the relation between the therapeutic effect and the AA profile in NASH patients with a prospective study. METHODS: We randomized 25 histologically proven NASH patients to diet treatment only or diet treatment plus pioglitazone (15 mg/day), and investigated the biological data for 24 months. We measured the concentrations of AAs and compared them between the beginning and the end of the study. RESULTS: Compared with the diet only group, pioglitazone therapy was associated with an increase in body weight (mean change -1.03 vs. +3.8 kg; p = 0.027) and subcutaneous fat (-3.7 vs. +45.7 cm(2); p = 0.056), and decreased ALT levels (-0.6 vs. -38.4 IU/L; p = 0.029) and HbA1c (0.33 vs. -0.29 %; p = 0.016). Regarding the AA profile, L-isoleucine, L-leucine, L-histidine, and L-lysine were significantly reduced in patients treated with pioglitazone. Furthermore, L-leucine was significantly reduced compared with those in the diet only group (mean change -34.8 vs. +4.12 nmol/mL; p = 0.032). Interestingly, there was a significant correlation between the changes in BCAAs, especially L-leucine, and those in ALT regardless of treatment with pioglitazone. CONCLUSIONS:Pioglitazone therapy in NASH subjects significantly reduced the plasma BCAA level and the degradation was closely related to the improvement of the ALT levels. These results suggest that pioglitazone improves insulin resistance and BCAA metabolism in NASH patients.
RCT Entities:
BACKGROUND AND AIMS: The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatitis (NASH). Thus, we investigated the relation between the therapeutic effect and the AA profile in NASH patients with a prospective study. METHODS: We randomized 25 histologically proven NASH patients to diet treatment only or diet treatment plus pioglitazone (15 mg/day), and investigated the biological data for 24 months. We measured the concentrations of AAs and compared them between the beginning and the end of the study. RESULTS: Compared with the diet only group, pioglitazone therapy was associated with an increase in body weight (mean change -1.03 vs. +3.8 kg; p = 0.027) and subcutaneous fat (-3.7 vs. +45.7 cm(2); p = 0.056), and decreased ALT levels (-0.6 vs. -38.4 IU/L; p = 0.029) and HbA1c (0.33 vs. -0.29 %; p = 0.016). Regarding the AA profile, L-isoleucine, L-leucine, L-histidine, and L-lysine were significantly reduced in patients treated with pioglitazone. Furthermore, L-leucine was significantly reduced compared with those in the diet only group (mean change -34.8 vs. +4.12 nmol/mL; p = 0.032). Interestingly, there was a significant correlation between the changes in BCAAs, especially L-leucine, and those in ALT regardless of treatment with pioglitazone. CONCLUSIONS:Pioglitazone therapy in NASH subjects significantly reduced the plasma BCAA level and the degradation was closely related to the improvement of the ALT levels. These results suggest that pioglitazone improves insulin resistance and BCAA metabolism in NASH patients.
Authors: Gunda Millonig; Stefanie Friedrich; Stefanie Adolf; Hamidreza Fonouni; Mohammad Golriz; Arianeb Mehrabi; Peter Stiefel; Gudrun Pöschl; Markus W Büchler; Helmut Karl Seitz; Sebastian Mueller Journal: J Hepatol Date: 2009-12-04 Impact factor: 25.083
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: James D Lewis; Assiamira Ferrara; Tiffany Peng; Monique Hedderson; Warren B Bilker; Charles P Quesenberry; David J Vaughn; Lisa Nessel; Joseph Selby; Brian L Strom Journal: Diabetes Care Date: 2011-04 Impact factor: 19.112
Authors: Brian A Irving; Rickey E Carter; Mattias Soop; Audrey Weymiller; Husnain Syed; Helen Karakelides; Sumit Bhagra; Kevin R Short; Laura Tatpati; Rocco Barazzoni; K Sreekumaran Nair Journal: Metabolism Date: 2015-01-22 Impact factor: 8.694
Authors: Luca A Lotta; Robert A Scott; Stephen J Sharp; Stephen Burgess; Jian'an Luan; Therese Tillin; Amand F Schmidt; Fumiaki Imamura; Isobel D Stewart; John R B Perry; Luke Marney; Albert Koulman; Edward D Karoly; Nita G Forouhi; Rasmus J O Sjögren; Erik Näslund; Juleen R Zierath; Anna Krook; David B Savage; Julian L Griffin; Nishi Chaturvedi; Aroon D Hingorani; Kay-Tee Khaw; Inês Barroso; Mark I McCarthy; Stephen O'Rahilly; Nicholas J Wareham; Claudia Langenberg Journal: PLoS Med Date: 2016-11-29 Impact factor: 11.069
Authors: Srilaxmi Kalavalapalli; Fernando Bril; Jeremy P Koelmel; Kaitlyn Abdo; Joy Guingab; Paige Andrews; Wen-Yi Li; Dhanya Jose; Richard A Yost; Reginald F Frye; Timothy J Garrett; Kenneth Cusi; Nishanth E Sunny Journal: Am J Physiol Endocrinol Metab Date: 2018-04-10 Impact factor: 4.310